CA2777807A1 - An assay method and devices involving the use of magnetic particles - Google Patents
An assay method and devices involving the use of magnetic particles Download PDFInfo
- Publication number
- CA2777807A1 CA2777807A1 CA2777807A CA2777807A CA2777807A1 CA 2777807 A1 CA2777807 A1 CA 2777807A1 CA 2777807 A CA2777807 A CA 2777807A CA 2777807 A CA2777807 A CA 2777807A CA 2777807 A1 CA2777807 A1 CA 2777807A1
- Authority
- CA
- Canada
- Prior art keywords
- assay device
- sample
- magnetic
- assay
- flow path
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000003556 assay Methods 0.000 title claims abstract description 189
- 239000006249 magnetic particle Substances 0.000 title claims abstract description 68
- 230000005291 magnetic effect Effects 0.000 claims abstract description 106
- 239000012491 analyte Substances 0.000 claims abstract description 66
- 238000000034 method Methods 0.000 claims abstract description 40
- 238000009739 binding Methods 0.000 claims abstract description 32
- 230000027455 binding Effects 0.000 claims abstract description 31
- 238000001514 detection method Methods 0.000 claims description 64
- 238000006243 chemical reaction Methods 0.000 claims description 52
- 239000000758 substrate Substances 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 13
- 238000000151 deposition Methods 0.000 claims description 10
- 230000002285 radioactive effect Effects 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 239000000020 Nitrocellulose Substances 0.000 claims description 7
- 230000004913 activation Effects 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 7
- 229920001220 nitrocellulos Polymers 0.000 claims description 7
- 150000007523 nucleic acids Chemical group 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- 108091023037 Aptamer Proteins 0.000 claims description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 6
- 206010036790 Productive cough Diseases 0.000 claims description 4
- 238000001574 biopsy Methods 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 230000002255 enzymatic effect Effects 0.000 claims description 4
- 210000002381 plasma Anatomy 0.000 claims description 4
- 210000003296 saliva Anatomy 0.000 claims description 4
- 210000003802 sputum Anatomy 0.000 claims description 4
- 208000024794 sputum Diseases 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 238000011002 quantification Methods 0.000 claims description 3
- 239000000523 sample Substances 0.000 description 92
- 239000002245 particle Substances 0.000 description 24
- 239000011324 bead Substances 0.000 description 17
- 108010074051 C-Reactive Protein Proteins 0.000 description 12
- 102100032752 C-reactive protein Human genes 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- 239000007791 liquid phase Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- -1 fleece Substances 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 239000000835 fiber Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 230000000979 retarding effect Effects 0.000 description 3
- 238000012289 standard assay Methods 0.000 description 3
- 239000012536 storage buffer Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229910000859 α-Fe Inorganic materials 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PDLGMYVCPJOYAR-DKIMLUQUSA-N Glu-Leu-Phe-Ala Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=CC=C1 PDLGMYVCPJOYAR-DKIMLUQUSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002657 fibrous material Substances 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000005082 bioluminescent agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011111 cardboard Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000005081 chemiluminescent agent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000005080 phosphorescent agent Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002454 poly(glycidyl methacrylate) polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5023—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures with a sample being transported to, and subsequently stored in an absorbent for analysis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/10—Integrating sample preparation and analysis in single entity, e.g. lab-on-a-chip concept
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0825—Test strips
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/16—Surface properties and coatings
- B01L2300/161—Control and use of surface tension forces, e.g. hydrophobic, hydrophilic
- B01L2300/163—Biocompatibility
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/0406—Moving fluids with specific forces or mechanical means specific forces capillary forces
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/043—Moving fluids with specific forces or mechanical means specific forces magnetic forces
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Clinical Laboratory Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Automatic Analysis And Handling Materials Therefor (AREA)
- Investigating Or Analyzing Materials By The Use Of Magnetic Means (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25240009P | 2009-10-16 | 2009-10-16 | |
| US61/252,400 | 2009-10-16 | ||
| SE0950762-5 | 2009-10-16 | ||
| SE0950762 | 2009-10-16 | ||
| PCT/EP2010/065600 WO2011045436A1 (en) | 2009-10-16 | 2010-10-18 | An assay method and devices involving the use of magnetic particles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2777807A1 true CA2777807A1 (en) | 2011-04-21 |
Family
ID=43334528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2777807A Abandoned CA2777807A1 (en) | 2009-10-16 | 2010-10-18 | An assay method and devices involving the use of magnetic particles |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2488871B1 (enExample) |
| JP (2) | JP2013507633A (enExample) |
| CN (1) | CN102753972B (enExample) |
| CA (1) | CA2777807A1 (enExample) |
| RU (1) | RU2595843C2 (enExample) |
| WO (1) | WO2011045436A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130210036A1 (en) * | 2012-01-20 | 2013-08-15 | Ortho-Clinical Diagnostics, Inc. | Controlling Fluid Flow Through An Assay Device |
| CA2882595C (en) * | 2012-08-21 | 2019-06-04 | Ortho-Clinical Diagnostics, Inc. | Antibodies to olanzapine haptens and use thereof |
| WO2014031662A2 (en) | 2012-08-21 | 2014-02-27 | Ortho-Clinical Diagnostics, Inc | Antibodies to olanzapine and use thereof |
| CN105102979B (zh) | 2013-01-29 | 2017-05-03 | 生物辐射海法有限公司 | 利用磁性纳米粒子的检测测定法 |
| CN112782393B (zh) * | 2013-03-11 | 2024-11-19 | 克忧健康公司 | 用于检测和量化分析物的系统和方法 |
| CN103308671B (zh) * | 2013-05-22 | 2016-02-03 | 北京康彻思坦生物技术有限公司 | 一种检测膜及检测系统 |
| CN103323603A (zh) * | 2013-06-07 | 2013-09-25 | 博奥生物有限公司 | 一种在磁珠表面共价偶联蛋白质的方法 |
| CN105531578B (zh) * | 2013-06-28 | 2018-06-12 | 丹麦技术大学 | 生物传感器及其相关方法 |
| JP6278772B2 (ja) * | 2014-03-19 | 2018-02-14 | テルモ株式会社 | 血糖値測定用チップ |
| JP6466775B2 (ja) | 2015-04-30 | 2019-02-06 | シスメックス株式会社 | 検体分析カートリッジを用いた検体分析方法、検体分析カートリッジ、および、検体分析装置 |
| WO2016182402A1 (ko) * | 2015-05-13 | 2016-11-17 | (주)에스엘에스 | 복수개의 금속 나노 태그를 이용한 복수개의 타겟의 동시 분석 방법 |
| CN105424922B (zh) * | 2015-12-09 | 2018-01-19 | 北京乐普医疗科技有限责任公司 | 基于磁珠包被抗体的微流控芯片及捕获心肌标志物的方法 |
| US11162938B2 (en) | 2017-03-28 | 2021-11-02 | Denka Company Limited | Membrane carrier, kit for testing liquid sample using same, and manufacturing method thereof |
| US11561197B2 (en) | 2018-06-29 | 2023-01-24 | AMMR Joint Venture | Electronic detection of a target based on enzymatic cleavage of a reporter moiety |
| US20210299656A1 (en) * | 2018-08-03 | 2021-09-30 | National Research Council Of Canada | Magnetic Nanoparticle Distribution in Microfluidic Chip |
| GB201818412D0 (en) * | 2018-11-12 | 2018-12-26 | Lumiradx Tech Ltd | A magnetic assembly for use in a device for conducting assays |
| CA3157610A1 (en) * | 2019-11-15 | 2021-05-20 | Redbud Labs, Inc. | Microfluidic device for and methods of using surface-attached posts and capture beads in a microfluidic chamber |
| WO2023141199A2 (en) * | 2022-01-21 | 2023-07-27 | Trustees Of Dartmouth College | Microtransfer patterning of magnetic materials for microfluidic applications |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6479302B1 (en) * | 1997-01-30 | 2002-11-12 | Merck Patent Gesellschaft Mit | Method for the immunological determination of an analyte |
| US6136549A (en) * | 1999-10-15 | 2000-10-24 | Feistel; Christopher C. | systems and methods for performing magnetic chromatography assays |
| US6607922B2 (en) * | 2000-03-17 | 2003-08-19 | Quantum Design, Inc. | Immunochromatographic assay method and apparatus |
| US7018849B2 (en) * | 2002-01-15 | 2006-03-28 | Piasio Roger N | Process for (A) separating biological/ligands from dilute solutions and (B) conducting an immunochromatographic assay thereof employing superparamagnetic particles throughtout |
| SE0201738D0 (sv) * | 2002-06-07 | 2002-06-07 | Aamic Ab | Micro-fluid structures |
| CN100405063C (zh) * | 2003-09-30 | 2008-07-23 | 江西中德生物工程有限公司 | 桔霉素免疫层析检测试纸及其制作方法与应用 |
| CN100334105C (zh) * | 2003-12-12 | 2007-08-29 | 上海交通大学 | 纳米磁性颗粒分离纯化链酶亲合素的方法 |
| SE0400662D0 (sv) * | 2004-03-24 | 2004-03-24 | Aamic Ab | Assay device and method |
| SE527036C2 (sv) * | 2004-06-02 | 2005-12-13 | Aamic Ab | Analysanordning med reglerat flöde och motsvarande förfarande |
| CN100389327C (zh) * | 2004-06-22 | 2008-05-21 | 北京倍爱康生物技术股份有限公司 | 一种甲状腺过氧化物酶抗体磁分离酶联免疫检测方法 |
| JP4791867B2 (ja) * | 2005-03-31 | 2011-10-12 | 日立マクセル株式会社 | 貴金属コート磁性粒子を用いた被検物質の検出方法 |
| WO2006134546A2 (en) | 2005-06-17 | 2006-12-21 | Koninklijke Philips Electronics N.V. | Accurate magnetic biosensor |
| SE528233C2 (sv) * | 2005-06-20 | 2006-09-26 | Aamic Ab | Metod och medel för att åstadkomma vätsketransport |
| GB2436616A (en) * | 2006-03-29 | 2007-10-03 | Inverness Medical Switzerland | Assay device and method |
| WO2007129275A2 (en) | 2006-05-10 | 2007-11-15 | Koninklijke Philips Electronics N.V. | Rapid magnetic biosensor |
| WO2007149043A1 (en) * | 2006-06-20 | 2007-12-27 | Åmic AB | Assay device |
| SE531948C2 (sv) | 2006-06-20 | 2009-09-15 | Aamic Ab | Analysanordning för vätskeprover innefattande filter i direkt kontakt med projektioner |
| US8409877B2 (en) | 2006-12-29 | 2013-04-02 | Intel Corporation | Enzymatic signal generation and detection of binding complexes in stationary fluidic chip |
| CN201087839Y (zh) * | 2007-03-30 | 2008-07-16 | 万华普曼生物工程有限公司 | 脑钠肽颜色颗粒诊断试纸 |
| WO2009009408A2 (en) | 2007-07-06 | 2009-01-15 | Applied Biosystems Inc. | Devices and methods for the detection of analytes |
| CN101315382B (zh) * | 2008-07-18 | 2012-12-05 | 中国检验检疫科学研究院 | 用于检测卡那霉素残留的免疫胶体金试纸条及其制备方法 |
-
2010
- 2010-10-18 CA CA2777807A patent/CA2777807A1/en not_active Abandoned
- 2010-10-18 JP JP2012533652A patent/JP2013507633A/ja active Pending
- 2010-10-18 CN CN201080057103.1A patent/CN102753972B/zh not_active Expired - Fee Related
- 2010-10-18 EP EP10774160.5A patent/EP2488871B1/en active Active
- 2010-10-18 WO PCT/EP2010/065600 patent/WO2011045436A1/en not_active Ceased
- 2010-10-18 RU RU2012120104/15A patent/RU2595843C2/ru not_active IP Right Cessation
-
2015
- 2015-09-17 JP JP2015183870A patent/JP6158266B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016035465A (ja) | 2016-03-17 |
| EP2488871B1 (en) | 2017-01-04 |
| JP6158266B2 (ja) | 2017-07-05 |
| EP2488871A1 (en) | 2012-08-22 |
| RU2012120104A (ru) | 2013-11-27 |
| CN102753972B (zh) | 2016-01-13 |
| CN102753972A (zh) | 2012-10-24 |
| WO2011045436A1 (en) | 2011-04-21 |
| RU2595843C2 (ru) | 2016-08-27 |
| JP2013507633A (ja) | 2013-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2488871B1 (en) | An assay method involving the use of magnetic particles | |
| RU2505816C2 (ru) | Картридж для анализов с помощью магнитных частиц | |
| US9575081B2 (en) | Device and methods for detecting analytes in saliva | |
| US20100311186A1 (en) | Devices and methods for performing receptor binding assays using magnetic particles | |
| US20130122517A1 (en) | Method of performing an assay | |
| CA2589071C (en) | Particle based binding assay | |
| KR20200141277A (ko) | 면역진단 키트 및 이를 이용한 면역진단 방법 | |
| US9823241B2 (en) | Processing of a sample fluid with target components | |
| JPH0580052A (ja) | 生体内物質の測定装置及び測定方法 | |
| JPH09229936A (ja) | 磁性粒子を用いる被検物質の測定方法並びに該方法に使用する担体及び測定器具 | |
| JP2000131320A (ja) | 特異的結合物質固定粒子を用いる被検物質の測定方法 | |
| BR112012008950A2 (pt) | método de ensaio e dispositivo que envolvem o uso de partículas magnéticas | |
| JPH11326327A (ja) | 粒子を使用する被検物質の測定方法及び測定器具 | |
| KR20040047144A (ko) | 미소체적 검출 방법 및 장치 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20151015 |
|
| FZDE | Dead |
Effective date: 20190529 |